Genentech, Inc.
1 DNA Way
South San Francisco
California
94080-4990
United States
Tel: 650-225-1000
Fax: 650-225-6000
Website: http://www.gene.com/
About Genentech, Inc.
Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for over 40 years. Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. We are among the world's leading biotech companies, with multiple products on the market and a promising development pipeline. Please take this opportunity to learn about Genentech where we believe that our employees are our most important asset & are dedicated to remaining a great place to work.
Connect with us!
Being a scientist at Genentech means being a drug discoverer. Mike Varney, head of Genentech Research and Early Development, explains how this culture of innovation is helping to solve some of the hardest biomedical problems of our time.
1422 articles with Genentech, Inc.
-
Genentech’s influenza treatment Xofluza® (baloxavir marboxil) has been granted approval by the U.S. Food and Drug Administration for use in people 12 years and older, making it the first single-dose post-exposure prophylaxis strategy approved by the agency.
-
Genentech Announces FDA Approval of Xofluza for the Prevention of Influenza Following Contact With an Infected Person
11/23/2020
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza® (baloxavir marboxil) as a treatment to prevent influenza in people 12 years of age and older following contact with someone with influenza (known as post-exposure prophylaxis)
-
OneOncology Partners with Genentech to Bring Personalized Cancer Research to Patients at Community Oncology Sites
11/23/2020
Collaboration Will Advance Comprehensive Genomic Profiling, Clinical Trials and Real-World Data Studies for Cancer Patients
-
Genentech to Present New Data Across 16 Blood Disorders at the American Society of Hematology 2020 Annual Meeting
11/5/2020
– New data for Genentech’s CD20xCD3 bispecific antibodies will be featured, as well as first clinical data on cevostamab, a first-of-its-kind FcRH5xCD3 bispecific antibody, in multiple myeloma – – Longer-term data for Genentech’s approved therapies in hemophilia A, chronic lymphocytic leukemia and diffuse large B-cell lymphoma reinforce the favorable efficacy and safety profile of each medicine –
-
Lodo Therapeutics Achieves Second Preclinical Milestone In Its Strategic Collaboration With Genentech
10/27/2020
Lodo's Informatics-Enabled Drug Discovery Platform Accesses the Vast Collections of Undiscovered Drug-Like Molecules Encoded in Microbial DNA
-
GO2 Foundation for Lung Cancer "Simply the Best" XV Virtual Gala Honors Those Working on the Front Lines to Fight Lung Cancer
10/22/2020
GO2 Foundation for Lung Cancer announced it will celebrate Genentech with the "Simply the Best Award" at its XV Virtual Annual Simply the Best Gala on November 14, 2020 at 6:30 pm PT.
-
Genesis Therapeutics Enters AI-driven, Multi-Target Drug Discovery Partnership with Genentech
10/19/2020
Genesis Therapeutics, a privately-held company inventing and deploying state-of-the-art artificial intelligence techniques to augment drug discovery and development, announced that it has entered into a multi-target collaboration agreement with Genentech, a member of the Roche Group.
-
In this multi-target partnership, Genentech will leverage Genesis’ Dynamic PotentialNet AI platform and other novel neural network algorithms.
-
Kineta to Extend Research Collaboration with Genentech to Develop a Novel Non-Opioid
10/8/2020
Collaboration to advance a first-in-class α9/α10 nAchR antagonist for the treatment of chronic pain into Phase 1 clinical trials
-
Forbion Portfolio Company, Enterprise Therapeutics’ First-in-Class TMEM16A Potentiator Program for Treatment of Cystic Fibrosis and Other Respiratory Diseases Acquired by Roche
10/7/2020
Forbion, a leading European life sciences venture capital firm, announces that its portfolio company, Enterprise Therapeutics Ltd ’s novel TMEM16A potentiator portfolio has been fully acquired by Roche and will be developed by Genentech, a member of the Roche Group.
-
Enterprise Therapeutics’ First-in-Class TMEM16A potentiator program for treatment of cystic fibrosis and other respiratory diseases acquired by Roche
10/7/2020
Enterprise’s novel TMEM16A potentiator portfolio includes ETD002, a first in class compound which is currently in Phase 1
-
This morning, the Swiss pharma giant acquired a portfolio of experimental cystic fibrosis therapies, including a candidate that has the potential to treat all patients with this disease.
-
Imbio Partners with Genentech to Develop Imaging Diagnostics for Lung Diseases
10/6/2020
Imbio, a leading provider of artificial intelligence solutions for medical imaging analysis, has partnered with Genentech, a member of the Roche Group, to develop quantitative imaging diagnostics for lung diseases.
-
Biopharma companies wrapped up September and headed into October with plenty of clinical trial news. Here’s a look.
-
"We are very excited to have entered into this transformative agreement that marks the start of a new era for Vaccibody,” Michael Engsig, CEO of Vaccibody, said in a statement.
-
Genentech Presents New 2-Year Data for Evrysdi (risdiplam) in Infants With Type 1 Spinal Muscular Atrophy (SMA)
9/28/2020
Exploratory efficacy data showed 88% of infants treated with Evrysdi were alive and did not require permanent ventilation at two years
-
Clinical Catch-Up: September 21-25
9/28/2020
The European Society of Medical Oncology (ESMO) Virtual Congress 2020 was last weekend and the beginning of the week, which resulted in numerous clinical trial announcements. Here’s a look. -
The drug failed to meet its primary efficacy endpoint, as well as two secondary endpoints.
-
Genentech, a Roche company, presented data from three Phase III trials of Tecentriq (atezolizumab) in triple-negative breast cancer at the European Society for Medical Oncology Virtual Congress 2020 this weekend.
-
Clinical Catch-Up: September 14-18
9/21/2020
It was a fairly busy week for clinical trial announcements, with some important and interesting news about COVID-19 treatments and vaccines, as well as numerous stories about non-COVID-19 studies.